Key terms
About GLPG
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GLPG news
Apr 08
10:27am ET
Galapagos NV Unveils CAR-T Therapy Advances
Apr 04
4:19pm ET
Galapagos announces clinical/ translational data on hematological cancer care
Apr 01
9:50am ET
Crocs initiated, Bill downgraded: Wall Street’s top analyst calls
Apr 01
6:11am ET
Galapagos downgraded to Underperform from Neutral at BofA
Mar 29
6:27pm ET
Galapagos NV Announces Shareholders’ Meetings and 2023 Report
Mar 29
7:01am ET
Galapagos NV Welcomes New Board Member
Mar 28
9:52am ET
Palantir downgraded, CyberArk initiated: Wall Street’s top analyst calls
Mar 28
6:07am ET
Galapagos downgraded to Underperform from Neutral at BofA
Mar 08
12:01pm ET
Galapagos price target lowered to EUR 35 from EUR 36 at Morgan Stanley
Mar 06
8:24pm ET
Galapagos assumed with an Equal Weight at Morgan Stanley
Feb 27
6:47am ET
Galapagos price target lowered to $41 from $44 at BofA
Feb 26
8:45pm ET
Galapagos (GLPG) Gets a Hold from RBC Capital
Feb 26
3:22pm ET
Galapagos price target lowered to EUR 33 from EUR 37 at Barclays
Feb 23
2:25pm ET
TD Cowen Sticks to Their Buy Rating for Galapagos (GLPG)
Feb 22
4:04pm ET
Galapagos reports FY23 revenue EUR 543.8M vs EUR 264M last year
Jan 31
4:09pm ET
Galapagos completes transfer of Jyseleca business to Alfasigma
No recent press releases are available for GLPG
GLPG Financials
Key terms
Ad Feedback
GLPG Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GLPG Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range